About crizo tinib
ALK and ROS1 tyrosine kinase inhibitor
Used for
- Treats certain ALK-positive or ROS1-positive non-small-cell lung cancers.
- Treats some ALK-positive inflammatory myofibroblastic tumors and anaplastic large-cell lymphomas.
Usual adult dose
250 mg by mouth twice daily for lung cancer; dosing for other conditions varies.
Usual dose in children
For eligible children, usually 280 mg/m² by mouth twice daily; specialist-directed dosing applies.
Common side effects
- Vision changes, nausea, diarrhea, vomiting, or constipation
- Swelling, fatigue, reduced appetite, or altered taste
- Abnormal liver tests or low blood-cell counts
- Slow heart rate or QT-related heart rhythm changes
Important warnings
- Can cause serious liver injury; liver tests require monitoring.
- May cause lung inflammation, severe vision problems, or abnormal heart rhythms.
- Can harm an unborn baby; effective contraception is needed during treatment.
- Dose adjustments may be needed for kidney problems or interacting medicines.
Pregnancy
May harm the fetus. Avoid pregnancy during treatment; discuss contraception and risks with the oncology team.
Breastfeeding
Breastfeeding is not recommended during treatment or for 45 days after the last dose.
Interactions
- Strong CYP3A inhibitors, such as clarithromycin, can raise crizotinib levels.
- Strong CYP3A inducers, such as rifampin, can lower crizotinib levels.
- Crizotinib can raise levels of some medicines, including certain statins and sedatives.
- Avoid medicines that prolong QT interval or slow heart rate when possible.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.